---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-000110"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2023-01-04T23:59:59+00:00"
generated_at: "2026-06-20T20:32:11.762272+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics effects 1-for-20 reverse stock split to meet Nasdaq minimum bid price

## Summary
- Reverse stock split at 1-for-20 ratio effective 5:00 p.m. ET on January 4, 2023.
- Shares outstanding reduced from 45,836,215 to approximately 2,291,811; no fractional shares issued, rounded up.
- Stock to trade split-adjusted on Nasdaq under symbol TENX starting January 5, 2023; new CUSIP 88032L506.
- Reverse split was approved by shareholders on June 9, 2022; board set ratio on December 15, 2022.
- Purpose is to regain compliance with Nasdaq's minimum $1.00 bid price requirement for continued listing.

## SEC filing metadata
- accession: 0001654954-23-000110
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2023-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495423000110/0001654954-23-000110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495423000110/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-000110
- JSON: https://secwatch.observer/filing/0001654954-23-000110.json
- Plain text: https://secwatch.observer/filing/0001654954-23-000110.txt

## Key facts
- Governance Changes
  TENAX THERAPEUTICS, INC.: Certificate of Amendment filed to effect reverse stock split of common stock at 1-for-20 ratio (effective 2023-01-04).
  - Change: charter amendment
  - Effective: 2023-01-04
  source text: Tenax Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Certificate of Incorporation, as amended (the “Certificate of Amendment”) with the Secretary of State of Delaware for the purpose of effecting a reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock at a ratio of one share for every 20 shares outstanding
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495423000110/0001654954-23-000110-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.